Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA6 | P23280 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA4 | P22748 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803073 | 0.84 | TPMT (0.54) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL21383062 | 0.81 | TSHR (0.55) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL29364242 | 0.79 | TPMT (0.58) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL2723610 | 0.79 | TPMT (0.58) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL76426 | 0.78 | CDC25B (0.55) | TPMTTSHRTP53CA1CA2 | |
| Hydrochloric Acid SCHEMBL8693394 | 0.77 | CDC25B (0.53) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL9080711 | 0.76 | KDM4E (0.52) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL351139 | 0.76 | CA12 (0.64) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL2952938 | 0.76 | MAPT (0.52) | TPMTTSHRTP53CA1CA2 | |
| SCHEMBL30574437 | 0.76 | CA12 (0.64) | TPMTTSHRTP53CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679472-A | Isoquinoline compounds with IRAK4 inhibitor activity | 北京桦冠医药科技有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC | 2017-10-19 | — | — | US | disclosed |
| WO-2016089990-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | TPMT 56/4885TSHR 3336/4885TP53 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.